NewsRx Logo Login/Signup
Home Newsletters Products Library About Us Contact -- Search NewsRx

NewsRx | Free Trials
Advertisement
VerticalNews | Global Warming
NewsRx | Free Newsletters
 
----------
------------
NewsRx on Facebook
-----
NewsRx Passes
Press Release Submissions
PR Login
-----
2008 Award Logo
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
-----
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.

Security by Verisign

Inflammation


Return to Library

Free Inflammation Articles


Research results from University of Michigan, Medical Department update understanding of dermatology



2009 AUG 4 - (NewsRx.com) -- In this recent report, researchers in the United States conducted a study "To examine clinical and molecular changes after topical fluorouracil treatment of photodamaged human facial skin for actinic keratoses. Nonrandomized, open-label 2-week treatment with fluorouracil cream, 5%, followed by clinical and molecular evaluation."

"Academic referral center. Twenty-one healthy volunteers, 56 to 85 years old, with actinic keratoses and photodamage. Twice-daily application of fluorouracil cream for 2 weeks and biopsies and clinical evaluation at baseline and periodically after treatment. Gene and protein expression of molecular effectors of epidermal injury, inflammation, and extracellular matrix remodeling 24 hours after fluorouracil treatment; clinical improvement measured by evaluators, photography, and patient questionnaires. One day after the final fluorouracil treatment, gene expression of the effectors of epidermal injury (keratin 16), inflammation (interleukin 1 beta), and extracellular matrix degradation (matrix metalloproteinases 1 and 3) was significantly increased. Types I and III procollagen messenger RNA were induced at week 4 (7-fold and 3-fold, respectively). Type I procollagen protein levels were increased 2-fold at week 24. Actinic keratoses and photoaging were statistically significantly improved. Most patients rated photoaging as improved and were willing to undergo the therapy again. Topical fluorouracil causes epidermal injury, which stimulates wound healing and dermal remodeling resulting in improved appearance," wrote D.L. Sachs and colleagues, University of Michigan, Medical Department.

The researchers concluded: "The mechanism of topical fluorouracil in photoaged skin follows a predictable wound healing pattern of events reminiscent of that seen with laser treatment of photoaging."

Sachs and colleagues published their study in Archives of Dermatology (Topical Fluorouracil for Actinic Keratoses and Photoaging A Clinical and Molecular Analysis. Archives of Dermatology, 2009;145(6):659-666).

For additional information, contact D.L. Sachs, University of Michigan, School Medical, Dept. of Dermatology, Taubman Center 1910, 1500 E Med Center Dr., Ann Arbor, MI 48109, USA.

Publisher contact information for the journal Archives of Dermatology is: American Medical Association, 515 N State St., Chicago, IL 60610-0946, USA.

Keywords: United States, Ann Arbor, Life Sciences, Protein Expression, Proteomics, Proteins, Fluorouracil, Pharmaceuticals, Drugs, Therapy, Treatment, Inflammation, Dermatology, University of Michigan, Medical Department.

This article was prepared by Life Science Weekly editors from staff and other reports. Copyright 2009, Life Science Weekly via NewsRx.com.

NewsRx NewsRx NewsRx
-----------------------
PR Login